Clinical Expertise

NCGS Laboratories, Inc. (NCGS), founded in 1984, is a full service Contract Research Organization (CRO) focused upon study management, data management, quality assurance and regulatory compliance. Our corporate experience encompasses clinical product development of a diverse group of pharmaceutical, biological, device, botanical and diagnostic products. Our current in-house expertise covers the following therapeutics areas.


Oncology | Transplant Medicine | Hematology
Indication PK QOL Study Phase Sites #Patients Completion Intl. Dom.
Squamous Cell Carcinoma of the Head and Neck - Refractory     II 40 120 2 years   X
Squamous Cell Carcinoma of the Head and Neck - Recurrent     III 40 360 2 years   X
    II 40 96 2 years   X
Multiple Myeloma PK   I 1 20 2 years   X
BMT Breast Cancer Stem Cell Select./ABMT     I 1 12 1 year X X
Breast Cancer ABMT     I 6 36 1 year   X
    III 1 60 1 year   X
Refractory Breast Cancer     Expanded Access 22 450 4 years X X
Small Cell Lung Cancer     III 12 200 2 years X X
BMT T Cell Depletion GVHD     I 1 20 1 year   X
    II 2 40 2 years   X
BMT/VOD PK   I 1 72 1 year   X
BMT/Delayed Engraftment     I 11 38 2 years   X
NHL     III 10 250 3 years   X
Renal Transplantation     I 1 40 1 year   X
ITP     Retrospective 1 28 1 month X X
Hemophilia     Retrospective 2 287 1 year X X
    II 2 30 1 year   X
    Retrospective 2 78 6 months X X
    IV 50 100 2 years X X
  QOL IV 100 400 2 years X X
  QOL IV 10 15 3 years X X
Cancer Related Pain*   QOL III 7 42 1.5 years   X
Esophageal Cancer   QOL Device 15 300 3 years X X
Haploidentical Stem Cell Transplantation     III 1 212 4 years   X
Haploidentical Stem Cell Transplantation     III 1 92 4 years   X
Recurrent High Grade Gliomas* PK QOL II 1 120 3 years   X
PK - Pharmacokinetic    QOL - Quality of Life    INTL - International    DOM - Domestic    * - Multiple Disease Indications